Recruiting PHASE1/PHASE2 INTERVENTIONAL 8-arm NCT06603844

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody Against Integrin avb8, in Patients With Advanced Solid Tumors

Sponsor: Corbus Pharmaceuticals Inc.

Conditions Solid Tumor

Interventions Anti-PD-1 monoclonal antibody CRB-601 monoclonal antibody

Updated 3 times since 2024 Last updated: May 29, 2025 Started: Dec 4, 2024 Primary completion: Nov 1, 2026 Completion: Dec 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Solid Tumor, this trial is actively recruiting participants. The trial is conducted by Corbus Pharmaceuticals Inc. and has accumulated 3 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Jun 2025 — Present [monthly]

Recruiting PHASE1/PHASE2
Jan 2025 — Jun 2025 [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Oct 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Corbus Pharmaceuticals Inc.

Data source: Corbus Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birkenhead, United Kingdom , Birmingham, United States , Chicago, United States , Cleveland, United States , Denver, United States , Durham, United States , Edinburgh, United Kingdom , Fairfax, United States , Glasgow, United Kingdom , La Jolla, United States and 14 more locations